



Company Advertorial

Jazz Pharmaceuticals in Australia and New Zealand

As the Sleep Down Under annual scientific meeting gets underway, we at Jazz Pharmaceuticals are thrilled to begin our support, excitingly for the first time as a local Australia/New Zealand affiliate after establishing our presence in these regions earlier this year.

As a long-time leader in sleep medicine globally, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our acquisition of GW Pharmaceuticals. We provide novel, life-changing medicines for people living with serious conditions, and we continue to expand our reach and capabilities to discover and develop new therapies that help people redefine what is possible in their lives.

As well as collaborating with partners, we are dedicated to broadening our global footprint and reaching as many people as we can. Building on years of positive experience in Australia, our latest expansion into this territory allows us to extend patient access and care.

At Jazz, we exist to innovate to improve the lives of patients and their families and we are incredibly proud to support the Australasian Sleep Association in this shared aspiration.

Adam Maguire - General Manager, Jazz ANZ (adam.maguire@jazzpharma.com)

Mark Tennyson - Medical Director, Jazz ANZ (mark.tennyson@jazzpharma.com)

Daniel Girdham – Sales & Marketing Manager, Jazz ANZ (daniel.girdham@jazzpharma.com)

Rene Francia – Medical Science Liaison, Jazz ANZ (rene.francia@jazzpharma.com)

Jazz Pharmaceuticals ANZ PTY Limited
One International Towers Sydney
Watermans Quay
Barangaroo NSW 2000
Australia